Poster: The Impact of Text Messaging and Pharmacist Outreach Interventions on Medication Adherence Rates in a Commercial PBM Population
Clinical Insights
May 29, 2025
Table of contentS
.jpg)
No items found.
Key Findings
- Capital Rx clients enrolled in the adherence program achieved an average improvement in adherence rate of 9.5% from baseline across all drug categories. In comparison, industry standard average improvement in adherence rates is 3%.
- The largest improvement in adherence rate (14%) was seen in the CCB and RASA drug classes, In these drug classes, we observe that 90% of claims were for a 90-day supply.
- The smallest improvement (1%) was seen in the diabetes drug class. Glucagon-like-pepetide-1- receptor agonists (GLP-1) accounted for 28% of the diabetes drug class. This may be due to the national GLP-1 drug shortage from 2022 to 2025.
Capital Rx's Angela Kalantarova, PharmD (Senior Clinical Program Manager), Jakob Deel, MBA Candidate, Nash Albadarin, PharmD, MBA (Associate Director, Clinical Programs), Lauren Carroll, PharmD, BCACP (Senior Manager, Clinical Programs), Bonnie Hui-Callahan, PharmD, CDCES (Senior Director, Clinical Programs), Jay Tran, PharmD, MHA (VP, Clinical Operations), and Sara Izadi, PharmD (Chief Clinical Officer) conducted a study seeking to measure the impact of Capital Rx’s adherence program on member adherence rates for medications used for diabetes, hypertension, and high cholesterol.
The team presented their research findings at the 2025 PQA Annual Meeting in Tampa, FL. Review or download the poster below to see their findings!
Related content
No items found.
